Italian Experts Develop New Guidelines for X-Linked Hypophosphatemia Treatment

X-linked hypophosphatemia (XLH) is a rare hereditary skeletal disorder that causes significant disability and quality of life impacts throughout a patient's lifetime. To address the complex management needs of these patients, a multidisciplinary working group of Italian experts in bone and mineral metabolism convened from October 2023 to April 2024 to develop comprehensive consensus guidelines.

The expert panel systematically reviewed randomized controlled trials, international guidelines based on GRADE criteria, and systematic reviews to formulate evidence-based statements. Their work focused on five critical areas of XLH management: clinical and biochemical diagnosis with disease progression monitoring, effects of conventional treatments using phosphate supplements and active vitamin D metabolites, effects of the newer treatment burosumab, multidisciplinary care approaches, and protocols for transitioning patients from pediatric to adult care.

The consensus emphasizes that individuals with XLH often experience significant unmet medical needs throughout their lives, requiring coordinated care from multiple specialists including endocrinologists, nephrologists, orthopedists, and other healthcare providers. The traditional treatment approach using phosphate supplements and active vitamin D metabolites, while helpful, has limitations in addressing the full spectrum of disease manifestations.

A major focus of the guidelines is burosumab, a newer therapeutic option that targets the underlying pathophysiology of XLH. The experts concluded that burosumab provides an effective and safe treatment option that can significantly reduce disease burden in both pediatric and adult patients. This represents a substantial advancement over conventional therapies, offering hope for improved outcomes and quality of life.

The panel strongly advocates for increased awareness of XLH among healthcare stakeholders, noting that the rarity of the condition often leads to delayed diagnosis and suboptimal management. They also call for revision of criteria and reimbursement policies for burosumab to ensure appropriate patient access to this promising therapy. The guidelines represent a significant step forward in standardizing care for this challenging rare disease across the patient lifespan.